ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab’s management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com


Đề xuất
PHONO Marks 20th Anniversary and Secures New Orders at RE+ 2026
A Seattle Startup Brings Your Pet to Life on Your Phone and Laptop With the Avatar Mirroring Their Every Move in Real Time
HEARTBOT AI Wins Chunghwa Telecom Special Award at Meet Neo Star 2026
Allooloo Tops 100M Capital Markets AI Agent Traffic a Month
KONST Showcases “24/7 GPUs Delivered in Asia” at SC26, Offering AI Compute Services from Validation and Delivery to Round-the-Clock Operations
APEC CEO Summit 2026 Concludes Successfully in Shenzhen